Genentech stops Erivedge IPF study before it starts
This article was originally published in Scrip
Genentech suspended patient recruitment for a Phase II clinical trial testing the hedgehog pathway inhibitor Erivedge (vismodegib) in the treatment of idiopathic pulmonary fibrosis (IPF) before the trial began enrolling patients.
You may also be interested in...
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.